MARiO : Predicting Cancer Variant Pathogenicity by Integrating In Silico Evaluation and Patient‐Level Mutational Contexts

Comprehensive genomic profiling (CGP) supports precision medicine in cancer care, but accurate assessment of missense variant pathogenicity, especially for variants without established consensus, remains challenging. Various computational tools have been developed for variant functional prediction, but most current tools rely solely on variant-level features and do not capture the clinical context of individual patients. To address this limitation, we developed MARiO (Missense Alteration Risk identifier in Oncology), a machine-learning model that integrates variant-level features and patient-level clinical and genomic contexts to effectively predict the pathogenicity of missense variants in cancer. We collected a total of 10,180 missense variants from 1271 patients and evaluated candidate features for their association with variant pathogenicity, identifying informative features including in silico functional predictions, population allele frequency, variant allele frequency, and tumor mutational burden. Using these selected features, MARiO was developed with extreme gradient boosting. The model integrates multiple in silico prediction tools and patient-specific genomic contexts while accommodating missing values frequently observed in real-world data. MARiO outperformed existing tools, achieving an area under the receiver operating characteristic curve of 0.922. The model demonstrated strong generalizability across multiple external datasets and showed consistency with real-world molecular treatment proposals. MARiO offers a robust and clinically relevant approach for missense variant pathogenicity assessment by integrating variant- and patient-level features and serves as a valuable tool to support clinical decision-making.

Authors

Institutions

Publication Details

Journal
Cancer Science
Published
2026-11-16
DOI
https://doi.org/10.1111/cas.70597
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

MARiO : Predicting Cancer Variant Pathogenicity by Integrating In Silico Evaluation and Patient‐Level Mutational Contexts

Takashi Kamatani, Sadakatsu Ikeda, Fuyuki Miya, Haruko Nakagawa et al.
3 links
Cancer Science
Genomics and Rare Diseases
article

MARiO : Predicting Cancer Variant Pathogenicity by Integrating In Silico Evaluation and Patient‐Level Mutational Contexts

Takashi Kamatani, Sadakatsu Ikeda, Fuyuki Miya, Haruko Nakagawa, Satoru Aoyama, Naoya Ishibashi, Michina Morioka
article en

Abstract

Comprehensive genomic profiling (CGP) supports precision medicine in cancer care, but accurate assessment of missense variant pathogenicity, especially for variants without established consensus, remains challenging. Various computational tools have been developed for variant functional prediction, but most current tools rely solely on variant-level features and do not capture the clinical context of individual patients. To address this limitation, we developed MARiO (Missense Alteration Risk identifier in Oncology), a machine-learning model that integrates variant-level features and patient-level clinical and genomic contexts to effectively predict the pathogenicity of missense variants in cancer. We collected a total of 10,180 missense variants from 1271 patients and evaluated candidate features for their association with variant pathogenicity, identifying informative features including in silico functional predictions, population allele frequency, variant allele frequency, and tumor mutational burden. Using these selected features, MARiO was developed with extreme gradient boosting. The model integrates multiple in silico prediction tools and patient-specific genomic contexts while accommodating missing values frequently observed in real-world data. MARiO outperformed existing tools, achieving an area under the receiver operating characteristic curve of 0.922. The model demonstrated strong generalizability across multiple external datasets and showed consistency with real-world molecular treatment proposals. MARiO offers a robust and clinically relevant approach for missense variant pathogenicity assessment by integrating variant- and patient-level features and serves as a valuable tool to support clinical decision-making.

Cancer Science
Keio University (JP), Tokyo Medical and Dental University Hospital (JP), Japanese Foundation For Cancer Research (JP)
Public Foundation of Chubu Science and Technology Center, Japan Society for the Promotion of Science
Good health and well-being
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon